SGLT2 inhibitor treatment for T2D has resulted in multifaceted favorable effects on blood glucose, blood pressure (BP), cardiovascular disease, and CKD progression (Hsia et al., 2017). The gene discussed is SLC5A2; the disease is chronic kidney disease.